摘要
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is characterized by inflammation of the interlobular bile ducts. Although PBC is a slowly progressive disease, with a natural history of 10–15 years leading to end-stage liver disease, highrisk cases may rapidly progress to decompensated cirrhosis or even death. As the most common autoimmune liver disease, the prevalence of PBC has been increasing globally, largely due to increased disease awareness, improved diagnosis, and treatment with ursodeoxycholic acid (UDCA). PBC is more likely to occur in middle-aged women, with a female-to-male ratio ranging from 1.6 to10;however, men have a higher disease severity [1,2].
作者
Yulong Shang
Patrick S.C.Leung
M.Eric Gershwin
Ying Han
尚玉龙;Patrick S.C.Leung;M.Eric Gershwin;韩英(National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Xijing Hospital,Air Force Military Medical University,Xi’an 710032,China;Division of Rheumatology,Allergy and Clinical Immunology,University of California,Davis 95616,USA)
基金
supported by the National Natural Science Foundation of China(81820108005 and 81900502)
the National Key Research and Development Program of China(2017YFA0105704)
Key Research and Development Program of Shaanxi(2021ZDLSF02-07)。
